UnitedHealth Group Says It Will Remove AbbVie's Blockbuster Rheumatoid Arthritis Drug Humira From Some Of Its Lists Of Preferred Drugs For Reimbursement As Of Jan. 1, 2025, And Recommend Less Expensive Biosimilar Versions Of The Medicine Instead
Portfolio Pulse from Benzinga Newsdesk
UnitedHealth Group plans to remove AbbVie's Humira from its preferred drug lists for reimbursement starting January 1, 2025, recommending cheaper biosimilar alternatives instead.
September 10, 2024 | 4:26 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
AbbVie's Humira will be removed from UnitedHealth's preferred drug lists, which may impact Humira's sales and AbbVie's revenue.
The removal of Humira from UnitedHealth's preferred lists could lead to decreased sales for AbbVie, negatively impacting its revenue.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
UnitedHealth Group will remove Humira from its preferred drug lists, potentially reducing costs by recommending cheaper biosimilars.
By removing Humira and recommending biosimilars, UnitedHealth could reduce drug costs, potentially improving its financial performance.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80